BioLineRx (NASDAQ:BLRX) Shares Cross Above 200 Day Moving Average – Time to Sell?

BioLineRx Ltd. (NASDAQ:BLRX)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.85 and traded as high as $3.10. BioLineRx shares last traded at $2.81, with a volume of 2,691 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioLineRx in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, BioLineRx has an average rating of “Sell”.

BioLineRx Stock Up 1.8%

The business has a 50-day simple moving average of $2.95 and a two-hundred day simple moving average of $2.85. The stock has a market capitalization of $12.28 million, a P/E ratio of -1.46 and a beta of 1.54. The company has a quick ratio of 1.43, a current ratio of 1.58 and a debt-to-equity ratio of 0.16.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.68. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The company had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $0.34 million.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.